Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 ...
Hosted on MSN1mon
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsWall Street analysts expect Gilead Sciences (GILD ... According to the collective judgment of analysts, 'Product Sales- AmBisome- U.S.' should come in at $7.44 million. The estimate indicates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback